N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial

Oral administration of N,N-Dimethylglycine (DMG), a tertiary amino acid, presumably enhances oxygen utilization by tissue and complex with free radicals. Beneficial effects are improved endurance performance and reduction fatigue in humans and animals. This pilot study reports the results over a one...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolfsegger, Thomas, Böck, Klaus, Schimetta, Wolfgang, von Oertzen, Tim J., Assar, Hamid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142643/
https://www.ncbi.nlm.nih.gov/pubmed/34024278
http://dx.doi.org/10.1186/s42466-021-00126-z
_version_ 1783696594358501376
author Wolfsegger, Thomas
Böck, Klaus
Schimetta, Wolfgang
von Oertzen, Tim J.
Assar, Hamid
author_facet Wolfsegger, Thomas
Böck, Klaus
Schimetta, Wolfgang
von Oertzen, Tim J.
Assar, Hamid
author_sort Wolfsegger, Thomas
collection PubMed
description Oral administration of N,N-Dimethylglycine (DMG), a tertiary amino acid, presumably enhances oxygen utilization by tissue and complex with free radicals. Beneficial effects are improved endurance performance and reduction fatigue in humans and animals. This pilot study reports the results over a one-year double-blind, placebo-controlled trial of DMG in 30 randomized patients with progressive multiple sclerosis. No treatment effects were found between the placebo group and the DMG group for disability, fatigue, cognitive, or gait parameters.
format Online
Article
Text
id pubmed-8142643
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81426432021-06-01 N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial Wolfsegger, Thomas Böck, Klaus Schimetta, Wolfgang von Oertzen, Tim J. Assar, Hamid Neurol Res Pract Letter to the Editor Oral administration of N,N-Dimethylglycine (DMG), a tertiary amino acid, presumably enhances oxygen utilization by tissue and complex with free radicals. Beneficial effects are improved endurance performance and reduction fatigue in humans and animals. This pilot study reports the results over a one-year double-blind, placebo-controlled trial of DMG in 30 randomized patients with progressive multiple sclerosis. No treatment effects were found between the placebo group and the DMG group for disability, fatigue, cognitive, or gait parameters. BioMed Central 2021-05-24 /pmc/articles/PMC8142643/ /pubmed/34024278 http://dx.doi.org/10.1186/s42466-021-00126-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Letter to the Editor
Wolfsegger, Thomas
Böck, Klaus
Schimetta, Wolfgang
von Oertzen, Tim J.
Assar, Hamid
N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial
title N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial
title_full N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial
title_fullStr N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial
title_full_unstemmed N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial
title_short N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial
title_sort n,n-dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142643/
https://www.ncbi.nlm.nih.gov/pubmed/34024278
http://dx.doi.org/10.1186/s42466-021-00126-z
work_keys_str_mv AT wolfseggerthomas nndimethylglycineinpatientswithprogressivemultiplesclerosisresultofapilotdoubleblindplacebocontrolledrandomizedclinicaltrial
AT bockklaus nndimethylglycineinpatientswithprogressivemultiplesclerosisresultofapilotdoubleblindplacebocontrolledrandomizedclinicaltrial
AT schimettawolfgang nndimethylglycineinpatientswithprogressivemultiplesclerosisresultofapilotdoubleblindplacebocontrolledrandomizedclinicaltrial
AT vonoertzentimj nndimethylglycineinpatientswithprogressivemultiplesclerosisresultofapilotdoubleblindplacebocontrolledrandomizedclinicaltrial
AT assarhamid nndimethylglycineinpatientswithprogressivemultiplesclerosisresultofapilotdoubleblindplacebocontrolledrandomizedclinicaltrial

Ejemplares similares